there is a question about who, financially, will have access to stem cellbased therapies.2 Also, given that some nations have legislated against allowing the use of embryonic stem cells, there may be a question of who legally will have access to therapies derived from banked stem cell lines, particularly those of embryonic derivation.
A final issue, and the one we will discuss in this paper, is who biologically will have access to cell-based therapies. As we will show, the biological properties of stem cells themselves may make them less accessible to some potential recipients than to others, a situation we term the problem of biological access. Unless the problem of biological access is carefully addressed, an American stem cell bank may end up benefiting primarily white Americans, to the relative exclusion of the rest of the population. We must therefore ask which of all possible ways to structure an American stem cell bank is the most just.
Rejection and the Theoretical Solution of Autologous Grafts
T he future promise of cell engineering is the ability to control cells and their functions. In the interim, however, it seems likely that cellbased treatment for disease and injury will be orchestrated through the transplantation of stem cells or their products. As with more conventional types of transplants, immune rejection is a major potential problem. Immune rejection is the principal reason that a given stem cell-based therapy for a specific disorder might be biologically less available to one patient than to another.
Immune rejection is mediated by our genetic makeup, specifically the set of genes which code for a type of protein called human leukocyte antigens (HLA). These HLA proteins are on the surface of virtually all cells in the body, including stem cells, and they play an important role in immune recognition and rejection. We have two copies of each of these genes, one inherited from each parent. There are multiple genes that code for HLA and we have two copies of each, one on each member of a chromosome pair. Some of the most important genes for the purposes of HLA-mediated immune recognition and response are HLA-A, HLA-B, and HLA-DR.
These genes are highly polymorphic, meaning they occur in variant forms, each of which is known as an allele. When an individual has two different alleles (one inherited from each parent), she is heterozygous for that allele. When, by chance, both parents pass on the same allele for a particular gene, their child is homozygous for that allele, meaning she has two identical copies of the allele.
Different methods exist for characterizing the alleles (either through A bank composed of the most common cell line haplotypes in the United States would favor the most populous group in the country. serologic or DNA methods), and the alleles are usually given numeric codes, like 0101. To find someone's HLA type is to determine which alleles she has at specific locations on the chromosome. Three locations-A, B, and DR-and thus three sets of alleles, are particularly important to HLA-mediated immune functioning. A match entails the donor and the recipient having the same HLA-A, HLA-B, and HLA-DR alleles.3 An individual's HLA type is linked to her ancestry; however, even within a family there is variability in HLA expression. Identical twins have identical HLA because they have received the same genetic contribution from their parents. Siblings have a roughly one in four chance of sharing an HLA type. By contrast, parents and children virtually never have identical HLA types since both parents contribute to the alleles of the child, and the chance of two parents with identical HLA types is remote.
In both bone marrow transplantation and certain types of solid organ transplantation, the match between the donor's and the recipient's HLA plays a crucial role in the acceptance or rejection of the transplant. Finding an identical match for anyone other than an identical twin is complicated by the highly polymorphic nature of HLA. The array of alleles that each person possesses is called her haplotype. If one has a relatively common HLA haplotype, finding a match may not be hard. For people with rarer haplotypes, a match may not be forthcoming. Mismatched transplants can be performed, but they are an inferior option to a matched transplant because they require increased levels of immunosuppressive drugs, which are themselves burdensome for patients and more frequently result in transplant-related complications. Some data suggest that the number of allele mismatches has a cumulative effect on negative outcomes; that is, there is a gradation of outcomes from good to poor as the number of mismatches increases. Thus, patients with more common haplotypes have a better chance of finding a matchor having biological access-and thus better odds of a successful transplant.
HLA has been demonstrated to track with geographical ancestry. For example, persons of sub-Saharan African ancestry have a greater variety of HLA types than do persons of any other geographical or ethnic grouping. A person's ancestry may significandy diminish (or increase) the odds of locating an HLA match-whether of certain solid organs, bone marrow, or stem cells.
Rejection is a major research area for transplantation. The search is on for a way to allow all patients, regardless of their haplotypes, to be able to receive a transplant that will work for them. Success in this search might eventually render the concept of biological access meaningless. For now, however, the problem of immune rejection is a real obstacle to clinical success.
Since an identical match between the donor and recipient significantly reduces concerns about immune rejection, autologous grafts, in which the recipient acts as her own donor, are thought to be a promising way to avoid rejection. Unfortunately, two such autologous solutions, somaticcell nuclear transfer and the isolation of existing stem cells from the patient's own body, are not practical at present.
In somatic-cell nuclear transfer (SCNT), a cell nucleus from the eventual transplant recipient is inserted into an oocyte from which the original nucleus has been removed, at which point the oocyte is triggered to develop. Although scientists have thus far failed to derive stem cells from human blastocysts created by SCNT, if such cells could be obtained, they would offer the recipient an exact genetic match (except for the mitochondrial genes, which do not affect HLA). Proponents of SCNT contend that this strategy could allow patients to receive customized HLAmatched therapies; however, the force of this claim is blunted by economic and logistical considerations. Although SCNT might, in theory, solve the rejection-biological access problem, it can do so only one person at a time. The amount of time and money needed to create these uniquely cloned solutions makes it unlikely that SCNT will provide a practical, widespread solution to the biological access problem. Additionally, for the foreseeable future, research in this area will continue to be overshadowed by political and moral controversy.
Some of the same limitations plague the second autologous strategy for solving the problem of rejection, that of using cells obtained directly from the patient herself through the identification and culturing of the patient's own adult stem cells.4 Some claim that it is possible, at least in animal models, to derive adult stem cells that exhibit the same degree of developmental capacity as embryonic stem cells. From a public policy perspective, the adult sources alternative has great appeal, as it sidesteps altogether the difficult issue of embryo destruction. Whether adult sources are able to replace embryonic sources remains to be seen.5 However, even if adult sources of stem cells are shown to be as robust as embryonic sources, using them to produce autologous stem cell-based therapies is problematic. At least for the near future, the laboratory procedures involved are extremely inefficient in generating sufficient cells. The isolation of adult stem cells yields very few cells, which are difficult to grow in culture. Like the cloning strategy, the adult stem cell strategy is both time consuming and expensive.
There may be some circumstances in which the time and expense required to prepare customized autologous therapies are justified. For example, a stem cell-based therapy that cures a young child of a burdensome condition, thereby saving the health care system a lifetime's worth of medical expenses while providing a profound benefit to the child, might justify the time and expense of creating an autologous therapy. For most conditions, however, the costs of customized autologous therapies would be prohibitive, even for wealthy nations. Moreover, for conditions such as stroke and injury, where treatments may need to be administered quickly in order to be maximally effective, it may never be possible to prepare autologous stem cell therapies from adult (or cloned) sources within the required time constraints. Although non-autologous transplants supported by immunosuppressive therapies could in theory be used to sustain stroke and trauma patients during the time required to prepare customized, autologous stem cell therapies, here, too, the costs are likely to be prohibitive. Therefore, adult sources are not much more likely than cloned sources to provide a complete solution to the rejection-biological access problem, at least for the foreseeable future. 
Alternative Strategies for

Unless the problem of biological access is carefully addressed, an
American stem cell bank may benefit white Americans to the relative exclusion of the rest of the population tribution and its relation to immune rejection for years, in particular with regard to patients who are less likely to find a match due to their ethnic or racial background. This concern will extend from solid organ and bone marrow transplantation to stem cell transplants because stem cells bear the haplotype of the individual from whom the cell line was derived. Although the need for HLA matching of stem cell-derived therapies will likely vary depending on the tissue that is transplanted, matching will be critical to clinical success in at least some important therapeutic applications. As such, the disparities currently present in the field of transplantation are likely to be replicated in the emerging practice of stem cell transplantation, unless specifically guarded against.
We have addressed elsewhere the issue of whether the existing stem cell lines are suitable for use in human recipients.20 Even assuming that current to find a match and therefore will face more burdensome therapeutic regimens that are less likely to be successful. Second, some groups of people may be systematically disadvantaged if their ancestral/ethnic group was not well represented in the biological material that was initially used to derive stem cells, since their haplotypes are then less likely to be included in stem cell-based therapies.
A Public Policy Response to the Problem of Biological Access
XW-e-strongly recommend that all W four of these strategies for dealing with immune rejection be actively pursued. Although the capacity to induce tolerance is currently in the earliest stages of clinical application, advances in this area hold great promise, not only for stem cell-based therapies but also for transplantation in general. Continued research into donation.23 In the context of stem cell-based therapies, however, the availability of HLA types need not be constrained by the vagaries of organ donation. Although we are not currently able to produce solid organs or tissues for transplantation, we are able to create stem cell lines that can be used for research and, eventually, therapies. This means that it is within our power to construct a bank of stem cell lines that includes a wide spectrum of HLA types, specifically selected to satisfy considerations of justice.
Many countries have had considerable experience with the creation and maintenance of banks of biological materials for therapeutic use. Biological banks exist for blood, sperm, corneas, and umbilical cord blood. In addition, there are systems of collection and distribution for solid organs and bone marrow. Most of these banks and systems are organized and financed by government or through Constructing a bank of homozygous lines will be difficult, not only because of the numerous ethical and political challenges we address later in this paper. The probability of finding homozygous spare embryos from in vitro fertilization clinics is, at best, low. A more promising but also more controversial strategy would build the bank around gamete donation. Embryos could be created from the gametes of donors who share a common haplotype; such embryos would have roughly a one in four chance of being homozygous for the relevant three alleles. If perfected, SCNT could provide a means to secure the desired stem cell lines from genetically appropriate homozygous adults. However, this procedure is even more morally and politically controversial than conventional embryo creation. It might also eventually be possible to develop the desired lines from selected cells of homozygous adults or from the cord blood of homozygous newborns, but at the moment it is still unclear whether these sources will prove sufficiently robust to completely replace the need for embryonic stem cell lines.
Although the obstacles to creating a public homozygous stem cell bank, which we discuss later, are formidable, creating such a bank is, we believe, technically feasible. Despite the increased efficiency (and thus desirability) of a homozygous bank, the number of lines needed to provide appropriate matches for all potential patients would still be prohibitively large. Identifying and soliciting female and male gametes that share a common haplotype, creating embryos from these gametes (only one in four of which will be homozygous), deriving stem cells from the selected embryo, and establishing a stem cell line is a difficult challenge. Additionally, some homozygous stem cell lines would be practically impossible to create because some haplotypes are so extraordinarily rare that finding the needed gametes or adult sources would be extremely difficult. Given these limitations, we believe that the only plausible strategy is to create a stem cell bank of limited size, containing homozygous stem cell lines chosen for development because they express some desired combination of HLA alleles.
The central ethical challenge of this proposition is determining which combination of haplotypes to include in the limited bank of homozygous cell lines intended for therapeutic use. The first step toward addressing this challenge is an assessment of the options. We think there are three main strategies, each highlighting different considerations of justice, for the selection of cell lines to be included in a limited, homozygous public stem cell bank. A straightforward maximizing approach would seek to include those cell lines from which the most matches could be made. An egalitarian approach would give all individuals who it is feasible to include in the bank an equal chance at having their haplotype represented. What we call an ethnic representation strategy would select common haplotypes within each ancestral/ethnic group so that the members of any group would have the same chance of finding a match with the banked cell lines. We consider each of these strategies and argue that the last is the most defensible.
Coverage Maximizing Strategy
The first strategy is to seek to include those homozygous cell lines that would allow the greatest percentage of the population to find a match in the bank. This strategy recognizes that not all cell lines are alike in terms of the number of people who might benefit from them. Some haplotypes are more common than others, and a limited bank can cover more people if it includes cell lines that possess the most common haplotypes. The obvious appeal of this strategy is that it provides for the largest number of potential beneficiaries of HLA matched stem cell-based treatments.
There are, however, two significant drawbacks to this approach. First, it ensures that persons with less common haplotypes could never benefit from the bank. One might reasonably be concerned about the fairness of such a strategy. Second, a bank composed of cell lines possessing the most common haplotypes in the United States would statistically favor white Americans simply because white Americans are the most populous group in the country.
The haplotypes that occur most commonly in white Americans overlap somewhat with the most common haplotypes of other American ancestral/ethnic groups, but significant diversity exists among the groups. (The overlap for five American ancestral/ethnic groups is illustrated in Table 1 .) Even with the overlaps shown here, not all ancestral/ethnic groups share common haplotypes. The most common HLA-A/B haplotype within white Americans, A 0101 B 0801, is among the ten most common for African Americans, Hispanics, and Native Americans; however, this haplotype is not among the twenty-five most common for Asian Americans. Moreover, the haplotypes presented in Table 1 are only HLA A-A/B; if HLA-DR were included, the overlap between ancestral/ethnic groups would decrease further.
Since white Americans are more numerous than America's other ancestral/ethnic groups, the inclusion of a haplotype found in a relatively small percentage of white Americans might extend coverage to more people than the inclusion of the haplotype most common in another ancestral/ethnic group. For this reason, if a bank included homozygous lines with the fifty most common haplotypes in the United States, the de facto result would be a bank composed primarily of lines whose haplotypes are common to white Americans. While this strategy would lead to a higher number of matches than any other, the matches would be clustered within the Caucasian ancestral group, exacerbating the health discrepancies that currently exist between ethnic groups within the United States-discrepancies that track histories of oppression and social injustice.
Equal Chances Strategy
One way of addressing the concern about fairness to individuals with less common haplotypes would be to give all haplotypes we can feasibly include in a bank, and thus all the individuals who have these haplotypes, an equal chance at being represented.25 As a practical matter, it is effectively impossible to create homozygous stem cell lines for haplotypes that are sufficiently rare. It would be possible, however, to include in a bank many haplotypes that fall somewhere in between the rare and the common ones. The equal chances strategy seeks to promote fairness by giving all persons with haplotypes that can feasibly be represented in the bank the same chance at biological access to stem cell-based therapies. This could be accomplished by randomizing the process through which eligible haplotypes are selected for inclusion in the bank (for example, through some form of lottery in which all the relevant haplotypes are included).
While providing as many individuals as possible an equal chance of benefiting from the bank may accord with some basic intuitions about fairness, adopting the equal chances strategy has two real drawbacks. First, this strategy is not designed to address the problem of unequal access for members of different ancestral or ethnic groups. In practice, the equal chances approach might either alleviate or exacerbate these inequalities, depending on the outcome of the lottery. In either case, however, these results would be due to luck, not design, and might lead to even greater disparities between ancestral/ethnic groups than the coverage maximizing strategy. Some might argue that the ethnic inequalities that might result from an equal chances strategy are more morally acceptable than those that would result from a coverage maximizing strategy because the process that yielded them is fair. However, those who hold that there are strong independent moral reasons to prevent further disadvantages for historically oppressed groups will not be satisfied by a process that might have this result.
Second, while a lottery might, as a matter of luck, lead to the inclusion of the same set of haplotypes as the coverage maximization strategy, the point of adopting the equal chances approach is to allow for other possibilities as well, including the possibility that most or all of the haplotypes included in the bank would be relatively uncommon. In this case, obviously, only a small number of persons would be able to benefit from the bank.
The problem that only a few might benefit from an equal chances efit the greatest number of patients should be constrained by the requirements of justice, and second, that justice requires that we give those with uncommon haplotypes an equal chance of benefiting from the bank. If these assumptions are correct, then the fact that the equal chances strategy provides benefits to fewer patients than the coverage maximization strategy does not show that the equal chances strategy should not be adopted. By the same token, however, the fact that some haplotype is so uncommon that creating a homologous stem cell line with that haplotype would absorb most of the resources available to a bank cannot show that we should exclude it from the lottery. But if our lottery must include all such haplotypes, the number of uncommon haplotypes would be larger than one might have thought, and the probability that the. bank would benefit only a very small number of people would be correspondingly greater.
that those who are less seriously ill or who are less likely to survive do not have an equal chance of securing the resource. Without some reason to regard the decision of which lines to include in a stem cell bank as different in kind from other decisions about the allocation of scarce resources to which no one is antecedently entitled, we should conclude that fairness does not require adoption of the equal chances strategy. Still another reason for rejecting the equal chances strategy is that, at least for some, the primary justification for investing in stem cell research and the creation of a public bank is the advancement of human welfare, generally. From this standpoint, a process of creating the bank that yields very little benefit would be selfdefeating. Whatever one thinks of the fairness of providing equal chances, we must not lose sight of the fact that in this instance we are seeking fairness within the context of advancing social An "ethnic representation" strategy should be adopted to avoid discrimination and underrepresentation in stem cell banks.
bank becomes more acute when we consider which haplotypes we might reasonably exclude from the lottery on the grounds that they are so rare that they cannot feasibly be included. We must exclude any haplotypes that are so rare that it would be literally impossible to find donors of the gametes needed to create them. If we also excluded haplotypes on the grounds that it would not be impossible but merely extremely difficult and costly to find such donors, we would have to do so because we judged that the costs of including those haplotypes in the lottery would outweigh the benefits of doing so. But to exclude haplotypes from the lottery on this basis is inconsistent with the justification for the equal chances strategy.
That justification relies on two claims: first, that our attempts to benWe do not believe that justice requires the adoption of the equal chances strategy. In designing a bank to provide maximal coverage, we do not deprive those with uncommon haplotypes of a benefit to which they are antecedently entitled or ask them to make sacrifices from which they cannot expect to benefit. We are, instead, in a situation in which we must decide how best to allocate scarce resources. In other such situations we do not believe that the only fair way to make decisions is by lottery. For instance, those who allocate other scarce medical resources, such as ICU beds or organs, do not rely on lotteries to make their decisions, and we do not generally think that these practices are unfair. Depending on the context, allocation decisions take into account such factors as medical need or prognosis, even though this means welfare. If there is too little welfare or benefit, the putative fairness promoted through equal chances comes at too high a price.
Ancestral/Ethnic Representation Strategy
A Ithough we the authors do not all ./lagree on this point,26 most of us would prefer to select the most common haplotypes from each of the major ancestral/ethnic groups in the United States in order to make the bank useful to the same percentage of patients from each ethnic category. This strategy would be less efficient than the coverage maximizing strategy because it would take more cell lines to match the same number of patients overall. This is true for two reasons. First, the ethnic representation strategy holds that we should ex-tend coverage to the same proportion of each ethnic group, even though a given percentage of a smaller group includes fewer people than the same percentage of a larger group. Second, different numbers of cell lines would be needed to cover the same percentage of different groups, due to the fact that some ethnic groups have more HLA diversity than others. For example, when matching for HLA-A, B, and DR, in order to ensure that roughly 50 percent of all white Americans and 50 percent of all African Americans could receive a suitable match, between sixty and eighty cell lines would be needed (Table 2) . Twenty homozygous cells lines would be sufficient to match 48.6 percent of white Americans, but only 28.7 percent of African Americans. In order make up most of the potential matches.
Since white Americans constitute 75 percent of the overall population,28 the haplotypes most common in this group are the most common in the U.S. population overall. If the ten most common haplotypes among white Americans (Table 1) were chosen for the stem cell bank, only three would overlap with the ten most common haplotypes for African Americans and Native Americans; there would be four overlaps with Hispanics, and none with Asian Americans. Thus, such a bank would provide matches for a much higher proportion of white Americans than of any other ancestral/ethnic group.29
On our proposal, fewer patients would have access to stem cell theraed in ways that make them worse.30 Insofar as they are the result of past injustices, as members of the society that produced them, we have an affirmative obligation to take steps to ameliorate them. For these reasons, it would be wrong to adopt policies that exacerbate the effects of discrimination, even if the factors that would serve to widen the disparity-for example, a higher rate of polymorphisms in one group as compared to another-are themselves unrelated to any historical or current social injustices.
Moreover, providing equal ethnic representation in a stem cell bank would prevent the expressive harm that would result from unequal representation. If we followed the coverage maximizing strategy, the resulting The ma existing human embryonic stem cell lines will not be sufficient to allow for equitable biological access.
to cover approximately 50 percent of each group, between twenty and thirty cell lines would be needed for white Americans and between forty and fifty for African Americans.
Matching for the DR alleles in addition to the A and B alleles decreases the likelihood of finding a match and increases the number of cell lines necessary to match a given percentage of a population. In some cases it may be reasonable to match only A and B, depending on the type of tissue transplanted and the likelihood of a good clinical outcome. When matching for HLA-A and B only, in order to cover 30 percent of each of the five ancestral/ethnic groups shown in Table 1, approximately twenty-three cell lines for African Americans, twelve for white Americans, twenty-four for Hispanics, fourteen for Native Americans, and twelve for Asian Americans would need to be established, for a total of eighty-five cell lines.27 By contrast, if the eighty-five most common haplotypes in the overall U.S. population were included (irrespective of ethnicity), white Americans would pies than would otherwise be the case. We do not take lightly the idea of designing a bank in such a way that fewer patients will be able to benefit from it. Nonetheless, we believe that the ethnic representation strategy should be adopted. In the United States, ancestral/ethnic groups other than white Americans are the only groups of persons that share two traits: first, they would be systematically underrepresented in a bank constructed according to the coverage maximization strategy, and second, they have endured a history of discrimination within American society. The coverage maximization strategy would both mimic this discrimination and exacerbate its effects, which in our view argues against its adoption.
As groups. Indeed, had the population genetics worked out differently, the coverage maximizing strategy could have affected ethnic groups quite differently. Nevertheless, if a bank made the benefits of stem cell therapy avail-able almost exclusively to white Americans, members of minority ancestral/ethnic groups might well wonder whether their interests had been taken seriously by those who decided which lines to include. Given the history of American race relations, and of the medical profession's treatment of non-white Americans, this concern cannot be dismissed as unreasonable.32 The need to avoid giving some persons reasonable grounds for concern about whether they are regarded as full and equal citizens whose interests are taken seriously, especially when those concerns have often been well founded, is a further reason to reject the coverage maximizing strategy.
While the ethnic representation approach is not maximally efficient, it does ensure that the greatest amount of benefit is produced consistent with an expression of respect for the fundamental equality of members of at least the major ancestral/ethnic groups in the United States.33 Given the country's history of oppression of a number of minority groups and the continued fragility of race relations, a policy that allowed further privileging of white Americans over other groups would signal a failure to acknowledge the equal worth of persons of all ethnic groups.
A Stem Cell Bank for Clinical Research
XWVe now turn to the question of how a research bank should be constructed. The goals of clinical research are distinct from the goals of clinical medicine, and so too are the relevant moral considerations. Everyone has an interest in research yielding its results as efficiently as possible and thus everyone has an interest in investigators being able to find appropriate human subjects quickly and easily. In contexts where HLA matching is thought to be important, it will be much easier to find eligible research subjects if the stem cell line from which the intervention is developed has a common haplotype. Thus in a research bank, as opposed to a therapeutic bank, the arguments favoring the equal chances strategy have no force. The arguments in favor of the ethnic representation strategy may also seem less persuasive, since the primary concern is to establish quickly whether a particular experimental treatment is indeed "safe and effective" and thus worth distributing to all.
We agree that a research bank should be designed to fit the needs of the research enterprise and thus that it should be comprosed primarily of homozygous stem cell lines for the most common haplotypes in the American population. However, there is a powerful argument for including at least several homozygous lines that are common in particular ancestral/ethnic groups. Without such lines, it is possible that researchers will be both less able and less likely to pursue the promise of stem cell science for diseases that occur disproportionately or present differently in different ethnic groups. If this were to occur, then it would not be possible for all to benefit fairly from society's investment in stem cell research. Assuming that there are good arguments for keeping the number of lines in a research bank to a minimum, a research bank of homozygous stem cell lines could likely function effectively with as few as fourteen lines-the six most common haplotypes of the population, which would match approximately 25 percent of all Americans (most of whom would be white Americans), as well as the two most common haplotypes in African Americans, Hispanics, Native Americans, and Asian Americans, which would match between 5 and 10 percent of the population in each of these ethnic groups (Table 1) .
Global Justice
In this paper, we focus on research and therapy banks for the United States, and our analysis of how to construct these banks justly is specific to the American context. In stem cell banks designed for other countries or for multi-national banks, considerations of justice may well be specified differently and thus different patterns of haplotypes may be required.
A particularly important worry from the perspective of justice is how fairly to accommodate the world's population as stem cell medicine progresses. Data from the population genetics literature indicates that populations in different regions are likely to have significantly different HLA frequencies-both different from each other and different from the U.S. population-thus potentially confounding efforts to make therapies widely available on a global scale. For example, sub-Saharan African populations exhibit the highest degree of genetic diversity globally,34 and this diversity is not well represented in groups in other world regions. Economic considerations would clearly come into play for countries in the global South, whose health care and health research budgets are already severely constrained-but again, this topic merits a separate analysis and is not the focus of our efforts. We assume that relatively rich countries will develop stem cell-based therapies and that eventually these products will be made financially available to those in poorer countries. To achieve biological access on a worldwide level, concerted effort and collaboration will be needed among developed nations pursuing stem cell-based therapies in order to consider genetic diversity in sufficiently broad terms to meet the needs of patients in resource-poor, as well as resource-rich, countries.
Moral and Political Challenges
T here are several significant challenges to creating patterned stem cell banks in the manner we have proposed. Assuming for the time being that the cell lines will be derived from embryonic sources, the first challenge will be the solicitation of gametes. Many people will need to be HLA typed in order to identify donors who have the desired haplotypes. Female donors will have to undergo the bur-densome process of ovarian hyperstimulation and oocyte retrieval, the risks and discomforts of which are not trivial. The acceptability of these risks turns in part on how they compare to the risks and discomforts of donating bone marrow or of being a living kidney or liver donor. Like these other transplantation donors, gamete donors to a stem cell bank should not be paid, thereby sharply distinguishing the banks from the practices of infertility programs. The burdens of ensuring a just system of access to stem cell therapies will fall disproportionately on women relative to men (for whom gamete donation is, by comparison, inconsequential). Whether women will be willing to become egg donors in the absence of financial compensation is unclear, although based on experience with the donation of bone marrow, kidneys, and livers, many people appear willing to assume medical burdens for the benefit of others. It is also possible that laboratory procedures will be developed to drive differentiation of human embryonic stem cells into oocytes,35 obviating the need for egg donations from individual women. This technology has not yet been fully worked out, and thus cannot yet be counted on for establishing a stem cell repository.
A related challenge will be securing sufficient gamete donations from minority populations and, in particular, from African Americans. The whole point of the ethnic representation strategy is to ensure that minorities are not systematically disadvantaged in access to stem cell therapies. At the same time, however, the African American community is distrustful of the medical and scientific establishment. This distrust manifests itself in many ways, including reluctance to consent to organ donation and reluctance to participate in medical research. Since constructing the banks as proposed will be impossible if African Americans and other minority groups do not participate in it, securing their trust and commitment will be essential.
The most obvious, and most formidable, challenge to creating stem cell banks in the United States is the widespread disagreement about the moral status of early human life. It is certain that a significant portion of the population will be opposed to the creation of such banks solely because they necessitate the creation and destruction of embryos. It may be difficult for politicians or governmental entities to support the idea of a patterned stem cell bank because of the amount of controversy surrounding this very contentious issue.
At least in the near term, creating the desired pattern of homozygous cell lines will require deriving lines from new embryonic sources. Developing a just system of access to the benefits of stem cell therapies would thus appear to require the instrumental creation and destruction of embryonic life.36 Therefore, we believe that it is morally desirable to delay creation of the therapy bank until there is solid evidence from early clinical trials that stem cell-based therapies will work. In the interim, we should examine the progress that is being made with non-embryonic sources of stem cells and with immunosuppression and tolerance-inducing techniques. If any of these approaches are significantly advanced by the time stem cell therapies are approaching clinical utility, it might render a therapy bank created through the destruction of embryos unnecessary.
At the same time, however, it is essential to establish a research stem cell bank in order to justly and safely proceed with human clinical investigation. Several avenues of research in stem cell science are approaching first human experiments. Elsewhere, we argue that the embryonic stem cell lines currently approved for federal funding are not appropriate for use in human beings.37 Unless adult sources of stem cells can, in the very near term, be determined to produce robust stem cell lines, it is likely that the transition from the laboratory to cinical investigation will require the destruction of additional human embryos. A patterned research bank constructed of homozygous lines of common haplotypes may actually minimize this use of embryos. Possibly as few as fourteen lines would provide a sufficiently broad base for clinical research, including the investigation of applications of particular interest to minority communities.
Another challenge will be identifying a structure for the research bank that will allow it to function as a public good and thus to fulfill its social purpose. A complicated web of proprietary interests has made it very difficult for researchers to effectively use existing stem cell lines. It is unclear whether a research bank could be constructed that could avoid this morass, particularly if it is not established or regulated by the federal government. Since federal involvement in a research bank is unlikely, funding will need to come from the private sector. Philanthropic support would be more likely to ensure that the bank operates as a true public good than would a consortium of commercial interests. By the time a therapy bank needs to be constructed, government involvement may be possible. For example, public values may shift, should the clinical utility of embryonic stem cell lines be established. Alternatively, non-embryonic cells might become reliable sources of stem cell lines, allowing the therapy bank to be constructed without the use of embryos.
Although there is encouraging progress in research on adult sources, we are not optimistic that there will be a technical fix for the moral and public policy quandaries posed here. It seems most likely to us that evidence of therapeutic value will be at hand before alternatives to embryonic sources will be found to be practical. Although we strongly support continued research into better immunosuppressive therapies and tolerance induction and believe that advances will be made in this area, it also seems unlikely to us that they will render the clinical advantages of HLA matching moot. Thus, we believe that society may well have to choose what it values more-ensuring that all benefit fairly from advances in stem cell science or protecting embryonic human life. If society decides to create a therapy bank, then every effort should be made to coordinate with similar efforts in other countries, in order to minimize the numbers of embryos that must be destroyed. The United Kingdom recently announced that it has already embarked on the creation of a stem cell bank of its own.38 It is not known at this writing whether the U.K. bank is being designed to address considerations of justice. It is also not clear what kind of HLA distribution is represented in the U.K. bank or whether immunologic matching would be possible for some proportion of the U.S. population.
Current and future policies concerning scientific research need to be responsive to the concerns about equitable biological access addressed in this paper. The existing human embryonic stem cell lines in the United States on which federally funded research is allowed will be insufficient to meet this goal. Federal restrictions on stem cell research will need to be re-evaluated, along with policies regarding funding priorities, patent protections, and incentives to the research community in order to ensure that justice concerns are adequately addressed as scientific research progresses. Although the process will be controversial, the need for equitable biological access to new therapies must be balanced with respect for early human life. Thoughtful discussion among scientists, policymakers, and the public about these challenging issues will help ensure that new therapies are developed fairly and responsibly.
